Page 46 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

Sequential therapy: sorafenib and regorafenib CGMH RWD and

optimized initiation of systemic agent with EOB MRI in HCC

Abstract:

HCC is the most common primary liver cancer. After image-guided tumor therapies such as TACE, RFA or
combination of both, CT and MRI perform a crucial role in assessing the therapeutic efficacy and
monitoring local tumor progression in the treated HCC during follow-up and early detection of a viable

tumor including residual tumor or local tumor progression. The robustness of imaging technique can
facilitate successful retreatment at an early stage. This lecture will focus on the sequential treatment survival
benefits and optimized initiation of systemic agent with EOB-MRI in advanced HCC, and what can we
conclude from existing dataset comparing the efficacy of Gd-EOB MRI vs MDCT as a follow-up diagnostic
testing for early and accurate detection of recurrence HCC after curative treatment.